CDK4/6-Inhibitors Inclusion in the Treatment of metastatic Hormone Receptor-positive, HER2-negative Breast Cancer

被引：0
|
作者：
Forstmeyer, D. [1 ]
机构：
[1] Univ Klinikum Leipzig, Univ Krebszentrum Leipzig UCCL, Liebigstr 20, D-04103 Leipzig, Germany
来源：
ONKOLOGE | 2016年 / 22卷 / 07期
关键词：
PALBOCICLIB;
D O I：
10.1007/s00761-016-0055-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：507 / 508
页数：2
相关论文
共 50 条
  • [1] CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
    Matutino, Adriana
    Amaro, Carla
    Verma, Sunil
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [2] Clinical efficacy of everolimus and CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer by treatment sequence
    Jeong, J. H.
    Jeong, H.
    Kim, J. E.
    Ahn, J-H.
    Jung, K. H.
    Kim, S-B.
    ANNALS OF ONCOLOGY, 2021, 32 : S72 - S73
  • [3] Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancer
    Sahin, Taha Koray
    Rizzo, Alessandro
    Guven, Deniz Can
    Aksoy, Sercan
    CANCER TREATMENT REVIEWS, 2025, 135
  • [4] CDK4/6 inhibitors for hormone receptor-positive HER2-negative metastatic breast cancer: does one size fit all?
    Fedele, Palma
    Cinieri, Saverio
    FUTURE MEDICINAL CHEMISTRY, 2019, 11 (11) : 1237 - 1239
  • [5] Elderly patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors in a multicentre cohort
    Pla, Helena
    Felip, Eudald
    Obadia, Veronica
    Pernas, Sonia
    Vinas, Gemma
    Margeli, Mireia
    Fort-Culillas, Roser
    Del Barco, Sonia
    Sabate, Nuria
    Fort, Eduard
    Lezcano, Clara
    Cirauqui, Beatriz
    Quiroga, Vanesa
    Stradella, Agostina
    Gil, Miguel Gil
    Esteve, Anna
    Recalde, Sabela
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1748 - 1758
  • [6] The Mutational Landscape of 1172 Patients with Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer Treated with CDK4/6 Inhibitors
    Shah, Ami N.
    Lim, Bora
    Mita, Monica M.
    Mauer, Elizabeth
    Layng, Kayla V.
    Chao, Calvin
    Brufsky, Adam M.
    CANCER RESEARCH, 2023, 83 (05)
  • [7] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Grinshpun, Albert
    Tolaney, Sara M. M.
    Burstein, Harold J. J.
    Jeselsohn, Rinath
    Mayer, Erica L. L.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [8] The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
    Albert Grinshpun
    Sara M. Tolaney
    Harold J. Burstein
    Rinath Jeselsohn
    Erica L. Mayer
    npj Breast Cancer, 9
  • [9] Expanding the Clinical Use of CDK4/6 Inhibitors in the Treatment of Hormone Receptor-Positive HER2-Negative Breast Cancer from Metastatic Setting to Adjuvant Setting
    Abdel-Razeq, Hikmat
    Sharaf, Baha'
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 727 - 735
  • [10] CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects
    Wekking, Demi
    Leoni, Vera Piera
    Lambertini, Matteo
    Dessi, Mariele
    Pretta, Andrea
    Cadoni, Andrea
    Atzori, Luigi
    Scartozzi, Mario
    Solinas, Cinzia
    CYTOKINE & GROWTH FACTOR REVIEWS, 2024, 75 : 57 - 64
12345